• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].偏头痛与头痛协会（德国偏头痛与头痛协会、奥地利头痛协会和瑞士头痛协会）关于偏头痛药物预防性治疗疗程的共识声明
Schmerz. 2023 Feb;37(1):5-16. doi: 10.1007/s00482-022-00671-9. Epub 2022 Oct 26.
2
[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].偏头痛与头痛学会（德国偏头痛与头痛协会、奥地利头痛协会和瑞士头痛协会）关于偏头痛药物预防性治疗疗程的共识声明
Nervenarzt. 2023 Apr;94(4):306-317. doi: 10.1007/s00115-022-01403-1. Epub 2022 Oct 26.
3
Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG).偏头痛和紧张型头痛的自我药疗：德国偏头痛和头痛学会（DMKG）、德国神经病学会（DGN）、奥地利头痛学会（ÖKSG）和瑞士头痛学会（SKG）循证推荐的摘要。
J Headache Pain. 2011 Apr;12(2):201-17. doi: 10.1007/s10194-010-0266-4. Epub 2010 Dec 23.
4
[Erratum to: Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].[勘误：偏头痛与头痛协会（德国偏头痛与头痛协会、奥地利头痛协会和瑞士头痛协会）关于偏头痛药物预防性治疗持续时间的共识声明]
Schmerz. 2023 Feb;37(1):17-18. doi: 10.1007/s00482-022-00691-5.
5
[Erratum to: Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].[勘误：偏头痛与头痛协会（德国偏头痛与头痛协会、奥地利头痛协会和瑞士头痛协会）关于偏头痛药物预防性治疗持续时间的共识声明]
Nervenarzt. 2023 Apr;94(4):318-319. doi: 10.1007/s00115-022-01435-7.
6
[Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society].[慢性偏头痛患者的治疗与护理：德国偏头痛与头痛协会/德国神经病学学会以及奥地利头痛协会/瑞士头痛协会的专家建议]
Nervenarzt. 2012 Dec;83(12):1600-8. doi: 10.1007/s00115-012-3680-9.
7
Incidence of migraine and tension-type headache in three different populations at risk within the German DMKG headache study.德国 DMKG 头痛研究中三种不同风险人群的偏头痛和紧张型头痛的发病率。
Cephalalgia. 2012 Mar;32(4):328-36. doi: 10.1177/0333102411428953. Epub 2011 Nov 24.
8
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients.德国偏头痛和头痛学会头痛登记处：前 1351 名患者的基线数据。
J Headache Pain. 2022 Jul 1;23(1):74. doi: 10.1186/s10194-022-01447-3.
9
[Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG)].[儿童特发性头痛的治疗——德国偏头痛与头痛协会（DMKG）的建议]
Schmerz. 2002 Feb;16(1):48-56. doi: 10.1007/s004820100073.
10
Regional variations in the prevalence of migraine and tension-type headache applying the new IHS criteria: the German DMKG Headache Study.应用国际头痛协会（IHS）新标准的偏头痛和紧张型头痛患病率的地区差异：德国DMKG头痛研究
Cephalalgia. 2009 Jan;29(1):48-57. doi: 10.1111/j.1468-2982.2008.01699.x. Epub 2008 Sep 2.

引用本文的文献

1
Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A-real-world data from a preliminary cohort study.erenumab对接受A型肉毒毒素治疗的慢性偏头痛患者的附加效应——一项初步队列研究的真实世界数据
Front Neurol. 2024 Jun 26;15:1370503. doi: 10.3389/fneur.2024.1370503. eCollection 2024.

偏头痛与头痛协会（德国偏头痛与头痛协会、奥地利头痛协会和瑞士头痛协会）关于偏头痛药物预防性治疗疗程的共识声明

[Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].

作者信息

Goßrau Gudrun, Förderreuther Stefanie, Ruscheweyh Ruth, Ruschil Victoria, Sprenger Till, Lewis David, Kamm Katharina, Freilinger Tobias, Neeb Lars, Malzacher Volker, Meier Uwe, Gehring Klaus, Kraya Torsten, Dresler Thomas, Schankin Christoph J, Gantenbein Andreas R, Brössner Gregor, Zebenholzer Karin, Diener Hans-Christoph, Gaul Charly, Jürgens Tim P

机构信息

Kopfschmerzambulanz, Universitätsschmerzcentrum, Medizinische Fakultät der TU Dresden, Universitätsklinikum Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.

Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Deutschland.

出版信息

Schmerz. 2023 Feb;37(1):5-16. doi: 10.1007/s00482-022-00671-9. Epub 2022 Oct 26.

DOI:10.1007/s00482-022-00671-9
PMID:36287263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9607711/
Abstract

Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.

摘要

偏头痛是最常见的神经系统疾病，并且可能与高度的残疾相关。除了采用非药物方法来降低偏头痛发作频率外，也有用于预防偏头痛的药物。德国偏头痛与头痛协会（DMKG）、德国神经病学学会（DGN）、奥地利头痛协会（ÖKSG）和瑞士头痛协会（SKG）发布了关于用药指征和应用的循证指南。对于诸如药物预防偏头痛的疗程等与治疗相关的问题，目前可得的研究数据无法得出结论。本综述的目的是提出一份治疗共识声明，该声明整合了当前的数据情况，并在缺乏数据时纳入专家意见。以下展示了由此得出的关于药物预防偏头痛疗程的当前建议。